Phio Pharmaceuticals Corp (NASDAQ: PHIO) open the trading on Thursday, with a bit cautious approach as it glided -3.23% to $2.4, before settling in for the price of $2.48 at the close. Taking a more long-term approach, PHIO posted a 52-week range of $0.97-$9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 66.30%. Meanwhile, its Annual Earning per share during the time was 66.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 82.60%. This publicly-traded company’s shares outstanding now amounts to $4.78 million, simultaneously with a float of $4.73 million. The organization now has a market capitalization sitting at $11.52 million. At the time of writing, stock’s 50-day Moving Average stood at $2.11, while the 200-day Moving Average is $2.28.
Phio Pharmaceuticals Corp (PHIO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Phio Pharmaceuticals Corp’s current insider ownership accounts for 1.38%, in contrast to 3.99% institutional ownership. According to the most recent insider trade that took place on Jun 10 ’25, this organization’s Chairman, Pres & CEO bought 2,000 shares at the rate of 2.42, making the entire transaction reach 4,840 in total value, affecting insider ownership by 27,149. Preceding that transaction, on Jun 10 ’25, Company’s Director bought 2,500 for 2.42, making the whole transaction’s value amount to 6,050. This particular insider is now the holder of 15,666 in total.
Phio Pharmaceuticals Corp (PHIO) Earnings and Revenue Records
Phio Pharmaceuticals Corp’s EPS increase for this current 12-month fiscal period is 82.60% and is forecasted to reach -0.83 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 64.39% through the next 5 years, which can be compared against the 66.30% growth it accomplished over the previous five years trading on the market.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Trading Performance Indicators
Let’s observe the current performance indicators for Phio Pharmaceuticals Corp (PHIO). It’s Quick Ratio in the last reported quarter now stands at 10.58.
In the same vein, PHIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.51, a figure that is expected to reach -0.36 in the next quarter, and analysts are predicting that it will be -0.83 at the market close of one year from today.
Technical Analysis of Phio Pharmaceuticals Corp (PHIO)
[Phio Pharmaceuticals Corp, PHIO] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 81.75% While, its Average True Range was 0.18.
Raw Stochastic average of Phio Pharmaceuticals Corp (PHIO) in the period of the previous 100 days is set at 62.73%, which indicates a major fall in contrast to 69.05% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 74.59% that was lower than 123.25% volatility it exhibited in the past 100-days period.
